From Medical Express:
An antibody treatment developed at Stanford Medicine successfully prepared patients for stem cell transplants without toxic busulfan chemotherapy or radiation, a Phase I clinical trial has shown.
Their work focused on CD117, which regulates the cells’ growth and development. They found that an antibody against CD117 blocked the stem cells’ growth and eliminated the cells from mice without the hazards of radiation and chemo. Together with other Stanford scientists, they subsequently identified the clinical antibody equivalent that was used in this new clinical trial. This clinical trial also addressed a second challenge in stem cell transplants: In the past, about 35% to 40% of patients who needed the transplants for any reason did not receive them because they lacked fully matched donors. But researchers found a way to increase the chance that the transplants would work by modifying the donated bone marrow before giving it to the participants.
More here.
Enjoying the content on 3QD? Help keep us going by donating now.